Global Burden of 5 Major Types of Gastrointestinal Cancer.
Aged
Americas
/ epidemiology
Asia
/ epidemiology
Australasia
/ epidemiology
Databases, Factual
/ statistics & numerical data
Europe
/ epidemiology
Female
Gastrointestinal Neoplasms
/ epidemiology
Geography
Global Burden of Disease
/ statistics & numerical data
Global Health
/ statistics & numerical data
Health Services Needs and Demand
Humans
Incidence
Liver Neoplasms
/ epidemiology
Male
Mass Screening
/ organization & administration
Mortality
/ trends
Pancreatic Neoplasms
/ epidemiology
Risk Factors
Sex Factors
Cancer
Epidemiology
Global
Incidence
Mortality
Risk Factors
Journal
Gastroenterology
ISSN: 1528-0012
Titre abrégé: Gastroenterology
Pays: United States
ID NLM: 0374630
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
19
12
2019
revised:
10
02
2020
accepted:
28
02
2020
pubmed:
6
4
2020
medline:
1
4
2021
entrez:
6
4
2020
Statut:
ppublish
Résumé
There were an estimated 4.8 million new cases of gastrointestinal (GI) cancers and 3.4 million related deaths, worldwide, in 2018. GI cancers account for 26% of the global cancer incidence and 35% of all cancer-related deaths. We investigated the global burden from the 5 major GI cancers, as well as geographic and temporal trends in cancer-specific incidence and mortality. Data on primary cancers of the esophagus, stomach, colorectum, liver, and pancreas were extracted from the GLOBOCAN database for the year 2018, as well as from the Cancer Incidence in 5 Continents series, and the World Health Organization mortality database from 1960 onward. Age-standardized incidence and mortality rates were calculated by sex, country, and level of human development. We observed geographic and temporal variations in incidence and mortality for all 5 types of GI cancers. Esophageal, gastric, and liver cancers were more common in Asia than in other parts of the world, and the burden from colorectal and pancreatic cancers was highest in Europe and North America. There was a uniform decrease in gastric cancer incidence, but an increasing incidence of colorectal cancer in formerly low-incidence regions during the studied time period. We found slight increases in incidence of liver and pancreatic cancer in some high-income regions. Although the incidence of some GI cancer types has decreased, this group of malignancies continues to pose major challenges to public health. Primary and secondary prevention measures are important for controlling these malignancies-most importantly reducing consumption of tobacco and alcohol, obesity control, immunizing populations against hepatitis B virus infection, and screening for colorectal cancer.
Sections du résumé
BACKGROUND & AIMS
There were an estimated 4.8 million new cases of gastrointestinal (GI) cancers and 3.4 million related deaths, worldwide, in 2018. GI cancers account for 26% of the global cancer incidence and 35% of all cancer-related deaths. We investigated the global burden from the 5 major GI cancers, as well as geographic and temporal trends in cancer-specific incidence and mortality.
METHODS
Data on primary cancers of the esophagus, stomach, colorectum, liver, and pancreas were extracted from the GLOBOCAN database for the year 2018, as well as from the Cancer Incidence in 5 Continents series, and the World Health Organization mortality database from 1960 onward. Age-standardized incidence and mortality rates were calculated by sex, country, and level of human development.
RESULTS
We observed geographic and temporal variations in incidence and mortality for all 5 types of GI cancers. Esophageal, gastric, and liver cancers were more common in Asia than in other parts of the world, and the burden from colorectal and pancreatic cancers was highest in Europe and North America. There was a uniform decrease in gastric cancer incidence, but an increasing incidence of colorectal cancer in formerly low-incidence regions during the studied time period. We found slight increases in incidence of liver and pancreatic cancer in some high-income regions.
CONCLUSIONS
Although the incidence of some GI cancer types has decreased, this group of malignancies continues to pose major challenges to public health. Primary and secondary prevention measures are important for controlling these malignancies-most importantly reducing consumption of tobacco and alcohol, obesity control, immunizing populations against hepatitis B virus infection, and screening for colorectal cancer.
Identifiants
pubmed: 32247694
pii: S0016-5085(20)30452-2
doi: 10.1053/j.gastro.2020.02.068
pmc: PMC8630546
mid: NIHMS1758791
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
335-349.e15Subventions
Organisme : Intramural NIH HHS
ID : Z01 CP000185
Pays : United States
Informations de copyright
Copyright © 2020 World Health Organization. Published by Elsevier Inc. All rights reserved.
Références
Gastroenterology. 2017 May;152(6):1319-1328.e7
pubmed: 28147224
Int J Cancer. 2019 Jan 1;144(1):49-58
pubmed: 29978474
CA Cancer J Clin. 2018 Jan;68(1):31-54
pubmed: 29160902
JAMA Oncol. 2016 Sep 1;2(9):1146-53
pubmed: 27196375
Cancer Epidemiol. 2012 Apr;36(2):e89-94
pubmed: 22189445
Gastroenterology. 2019 Jan;156(1):59-62.e4
pubmed: 30267713
JAMA Oncol. 2016 Sep 1;2(9):1154-61
pubmed: 27196525
Acta Oncol. 2016 Sep - Oct;55(9-10):1158-1160
pubmed: 27551890
Gut. 2015 Oct;64(10):1637-49
pubmed: 26041752
Eur J Cancer Prev. 2018 Mar;27(2):124-133
pubmed: 27560662
J Natl Cancer Inst. 2006 Oct 18;98(20):1445-52
pubmed: 17047193
Curr Epidemiol Rep. 2019 Jun;6(2):104-111
pubmed: 31259140
Lancet Gastroenterol Hepatol. 2020 Jan;5(1):42-54
pubmed: 31648970
Helicobacter. 2013 Oct;18(5):325-37
pubmed: 23566268
J Natl Cancer Inst. 2017 Aug 1;109(8):
pubmed: 28376186
JAMA. 2008 Dec 17;300(23):2765-78
pubmed: 19088354
Lancet Gastroenterol Hepatol. 2019 Dec;4(12):913-933
pubmed: 31648977
Cancer Res Treat. 2019 Apr;51(2):417-430
pubmed: 30913865
J Natl Cancer Inst. 2018 Jun 1;110(6):608-615
pubmed: 29361173
World J Gastroenterol. 2007 Oct 28;13(40):5367-70
pubmed: 17879408
J Natl Cancer Inst. 2009 Oct 7;101(19):1348-55
pubmed: 19759364
BMC Cancer. 2018 Aug 3;18(1):784
pubmed: 30075763
Gut. 2015 Dec;64(12):1881-8
pubmed: 25748648
Nat Rev Clin Oncol. 2012 Mar 20;9(5):278-87
pubmed: 22430857
N Engl J Med. 2018 May 03;378(18):1734-1740
pubmed: 29580179
Lancet. 2008 Feb 16;371(9612):569-78
pubmed: 18280327
Cancer Epidemiol. 2016 Apr;41:88-95
pubmed: 26851752
J Glob Oncol. 2018 Sep;4:1-9
pubmed: 30241229
Lancet Gastroenterol Hepatol. 2019 Jul;4(7):511-518
pubmed: 31105047
Gastroenterology. 2019 Apr;156(5):1416-1427
pubmed: 30611753
Gastroenterology. 2018 Jan;154(2):360-373
pubmed: 28823862
Int J Cancer. 2017 Jun 15;140(12):2709-2715
pubmed: 28281292
Nat Rev Dis Primers. 2016 Apr 21;2:16022
pubmed: 27158978
Lancet. 2016 Apr 2;387(10026):1377-1396
pubmed: 27115820
Gut. 2011 Dec;60(12):1644-9
pubmed: 21613644
Am J Gastroenterol. 2017 Aug;112(8):1247-1255
pubmed: 28585555
Lancet Oncol. 2019 Nov;20(11):1493-1505
pubmed: 31521509
Gut. 2015 Mar;64(3):381-7
pubmed: 25320104
BMJ. 2014 May 20;348:g3174
pubmed: 24846275
Gut Liver. 2018 May 15;12(3):236-245
pubmed: 28783896
Lancet. 2005 Oct 8;366(9493):1303-14
pubmed: 16214602
Lancet. 2018 Mar 17;391(10125):1023-1075
pubmed: 29395269
Lancet. 2016 Apr 9;387(10027):1513-1530
pubmed: 27061677
JAMA Intern Med. 2016 Jun 1;176(6):816-25
pubmed: 27183032
Indian J Gastroenterol. 2005 Sep-Oct;24(5):224
pubmed: 16361775
Asian Pac J Cancer Prev. 2010;11(3):595-9
pubmed: 21039022
J Clin Oncol. 2015 Jun 10;33(17):1951-7
pubmed: 25940715
Gastroenterology. 2017 Aug;153(2):420-429
pubmed: 28456631
J Gastroenterol. 2019 Aug;54(8):669-673
pubmed: 31172291
Lancet Glob Health. 2018 May;6(5):e555-e567
pubmed: 29653628
N Engl J Med. 1997 Jun 26;336(26):1855-9
pubmed: 9197213
Gut. 2019 Oct;68(10):1820-1826
pubmed: 31097539
Lancet Glob Health. 2020 Feb;8(2):e180-e190
pubmed: 31862245
Ann Oncol. 2011 Sep;22(9):1958-1972
pubmed: 21307158
Epidemiol Rev. 1986;8:1-27
pubmed: 3533579
BMC Med. 2018 Aug 21;16(1):125
pubmed: 30126408
Lancet Oncol. 2015 Dec;16(16):1599-600
pubmed: 26514947
Lancet Gastroenterol Hepatol. 2019 Dec;4(12):934-947
pubmed: 31648972
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Jpn J Clin Oncol. 2018 Jul 01;48(7):673-683
pubmed: 29889263
Lancet Public Health. 2019 Mar;4(3):e137-e147
pubmed: 30733056
Lancet Oncol. 2015 Jan;16(1):36-46
pubmed: 25467404
Int J Epidemiol. 2012 Dec;41(6):1706-18
pubmed: 23148106
Int J Cancer. 2017 Nov 15;141(10):1950-1962
pubmed: 28718913
Int J Cancer. 2020 Jul 15;147(2):317-330
pubmed: 31597196
Int J Cancer. 2002 Mar 10;98(2):241-56
pubmed: 11857415